Boston Scientific Corp (BSX) - Net Assets

Latest as of September 2025: $23.63 Billion USD

Based on the latest financial reports, Boston Scientific Corp (BSX) has net assets worth $23.63 Billion USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($42.71 Billion) and total liabilities ($19.08 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BSX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	$23.63 Billion
% of Total Assets	55.33%
Annual Growth Rate	18.12%
5-Year Change	43.56%
10-Year Change	248.15%
Growth Volatility	58.2

Boston Scientific Corp - Net Assets Trend (1991–2024)

This chart illustrates how Boston Scientific Corp's net assets have evolved over time, based on quarterly financial data. Also explore how large is Boston Scientific Corp's balance sheet for the complete picture of this company's asset base.

Annual Net Assets for Boston Scientific Corp (1991–2024)

The table below shows the annual net assets of Boston Scientific Corp from 1991 to 2024. For live valuation and market cap data, see how much is Boston Scientific Corp worth.

Year	Net Assets	Change
2024-12-31	$22.00 Billion	+12.66%
2023-12-31	$19.53 Billion	+11.13%
2022-12-31	$17.57 Billion	+5.72%
2021-12-31	$16.62 Billion	+8.46%
2020-12-31	$15.33 Billion	+10.45%
2019-12-31	$13.88 Billion	+59.05%
2018-12-31	$8.72 Billion	+24.45%
2017-12-31	$7.01 Billion	+4.13%
2016-12-31	$6.73 Billion	+6.53%
2015-12-31	$6.32 Billion	-7.64%
2014-12-31	$6.84 Billion	+4.65%
2013-12-31	$6.54 Billion	-4.82%
2012-12-31	$6.87 Billion	-39.49%
2011-12-31	$11.35 Billion	+0.50%
2010-12-31	$11.30 Billion	-8.17%
2009-12-31	$12.30 Billion	-6.37%
2008-12-31	$13.14 Billion	-12.98%
2007-12-31	$15.10 Billion	-1.31%
2006-12-31	$15.30 Billion	+257.26%
2005-12-31	$4.28 Billion	+6.39%
2004-12-31	$4.03 Billion	+40.64%
2003-12-31	$2.86 Billion	+16.01%
2002-12-31	$2.47 Billion	+22.43%
2001-12-31	$2.02 Billion	+4.13%
2000-12-31	$1.94 Billion	+12.24%
1999-12-31	$1.72 Billion	+109.96%
1998-12-31	$821.10 Million	-16.74%
1997-12-31	$986.20 Million	+7.63%
1996-12-31	$916.30 Million	+21.69%
1995-12-31	$753.00 Million	+121.47%
1994-12-31	$340.00 Million	+37.82%
1993-12-31	$246.70 Million	-0.96%
1992-12-31	$249.10 Million	+175.86%
1991-12-31	$90.30 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Boston Scientific Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 3802.2% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	$2.67 Billion	12.28%
Common Stock	$17.00 Million	0.08%
Other Comprehensive Income	$275.00 Million	1.26%
Other Components	$18.80 Billion	86.38%
Total Equity	$21.77 Billion	100.00%

Boston Scientific Corp Competitors by Market Cap

The table below lists competitors of Boston Scientific Corp ranked by their market capitalization.

Company	Market Cap
ING Group NV ADR NYSE:ING	$80.23 Billion
Brookfield Asset Management Inc NYSE:BAM	$80.23 Billion
Eoptolink Technology Inc Ltd SHE:300502	$80.24 Billion
The Bank of New York Mellon Corporation NYSE:BK	$80.26 Billion
Barclays PLC MX:BCSN	$79.83 Billion
BYD Co Ltd Class A SHE:002594	$79.53 Billion
Emerson Electric Company NYSE:EMR	$79.42 Billion
ADVANTEST ADR NEW/1 O.N. F:VANA	$79.38 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Boston Scientific Corp's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 19,282,000,000 to 21,770,000,000, a change of 2,488,000,000 (12.9%).
Net income of 1,854,000,000 contributed positively to equity growth.
Share repurchases of 230,000,000 reduced equity.
Other comprehensive income increased equity by 226,000,000.
Other factors increased equity by 638,000,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	$1.85 Billion	+8.52%
Share Repurchases	$230.00 Million	-1.06%
Other Comprehensive Income	$226.00 Million	+1.04%
Other Changes	$638.00 Million	+2.93%
Total Change	$-	12.90%

Book Value vs Market Value Analysis

This analysis compares Boston Scientific Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.68x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 226.95x to 3.68x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1991-12-31	$0.24	$53.93	x
1992-12-31	$0.64	$53.93	x
1993-12-31	$0.62	$53.93	x
1994-12-31	$0.81	$53.93	x
1995-12-31	$1.02	$53.93	x
1996-12-31	$1.15	$53.93	x
1997-12-31	$1.23	$53.93	x
1998-12-31	$1.06	$53.93	x
1999-12-31	$2.09	$53.93	x
2000-12-31	$2.36	$53.93	x
2001-12-31	$2.43	$53.93	x
2002-12-31	$2.98	$53.93	x
2003-12-31	$3.40	$53.93	x
2004-12-31	$4.70	$53.93	x
2005-12-31	$5.11	$53.93	x
2006-12-31	$12.01	$53.93	x
2007-12-31	$10.15	$53.93	x
2008-12-31	$8.77	$53.93	x
2009-12-31	$8.16	$53.93	x
2010-12-31	$7.44	$53.93	x
2011-12-31	$7.47	$53.93	x
2012-12-31	$4.88	$53.93	x
2013-12-31	$4.88	$53.93	x
2014-12-31	$5.08	$53.93	x
2015-12-31	$4.71	$53.93	x
2016-12-31	$4.89	$53.93	x
2017-12-31	$5.03	$53.93	x
2018-12-31	$6.23	$53.93	x
2019-12-31	$9.84	$53.93	x
2020-12-31	$10.82	$53.93	x
2021-12-31	$11.59	$53.93	x
2022-12-31	$12.21	$53.93	x
2023-12-31	$13.18	$53.93	x
2024-12-31	$14.65	$53.93	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Boston Scientific Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 8.52%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 11.07%
• Asset Turnover: 0.43x
• Equity Multiplier: 1.81x
Recent ROE (8.52%) is above the historical average (5.77%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1991	46.29%	18.17%	1.67x	1.52x	$32.77 Million
1992	22.72%	17.96%	1.05x	1.20x	$31.69 Million
1993	28.25%	18.34%	1.18x	1.31x	$45.03 Million
1994	23.44%	17.75%	1.04x	1.27x	$45.70 Million
1995	1.06%	0.72%	1.03x	1.43x	$-67.30 Million
1996	18.24%	11.43%	0.97x	1.65x	$75.47 Million
1997	14.12%	7.44%	0.95x	2.00x	$40.68 Million
1998	-32.20%	-11.84%	0.57x	4.74x	$-346.51 Million
1999	21.52%	13.05%	0.80x	2.07x	$198.60 Million
2000	19.28%	14.00%	0.78x	1.77x	$179.50 Million
2001	-2.68%	-2.02%	0.67x	1.97x	$-255.50 Million
2002	15.12%	12.78%	0.66x	1.80x	$126.30 Million
2003	16.49%	13.58%	0.61x	1.99x	$185.80 Million
2004	26.39%	18.88%	0.69x	2.03x	$659.50 Million
2005	14.67%	10.00%	0.77x	1.91x	$199.80 Million
2006	-23.38%	-45.74%	0.25x	2.03x	$-5.11 Billion
2007	-3.28%	-5.92%	0.27x	2.07x	$-2.00 Billion
2008	-15.50%	-25.29%	0.30x	2.06x	$-3.35 Billion
2009	-8.33%	-12.52%	0.33x	2.05x	$-2.26 Billion
2010	-9.43%	-13.64%	0.35x	1.96x	$-2.19 Billion
2011	3.88%	5.79%	0.36x	1.88x	$-694.30 Million
2012	-59.21%	-56.12%	0.42x	2.50x	$-4.75 Billion
2013	-1.85%	-1.69%	0.43x	2.56x	$-774.90 Million
2014	-1.74%	-1.61%	0.44x	2.46x	$-803.30 Million
2015	-3.78%	-3.20%	0.41x	2.87x	$-871.00 Million
2016	5.15%	4.14%	0.46x	2.69x	$-326.30 Million
2017	1.48%	1.15%	0.48x	2.72x	$-597.10 Million
2018	19.15%	17.01%	0.47x	2.41x	$798.50 Million
2019	33.87%	43.78%	0.35x	2.20x	$3.31 Billion
2020	-0.54%	-0.83%	0.32x	2.01x	$-1.61 Billion
2021	6.26%	8.75%	0.37x	1.94x	$-622.30 Million
2022	3.97%	5.50%	0.39x	1.85x	$-1.06 Billion
2023	8.26%	11.19%	0.41x	1.82x	$-335.20 Million
2024	8.52%	11.07%	0.43x	1.81x	$-323.00 Million

Industry Comparison

This section compares Boston Scientific Corp's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $376,837,339
Average return on equity (ROE) among peers: -92.91%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Boston Scientific Corp (BSX)	$23.63 Billion	46.29%	0.81x	$79.98 Billion
Abbott Laboratories (ABT)	$3.20 Billion	33.99%	0.95x	$146.62 Billion
Adagio Medical Holdings, Inc Common Stock (ADGM)	$-95.88 Million	0.00%	0.00x	$20.65 Million
Aethlon Medical Inc (AEMD)	$-3.32 Million	0.00%	0.00x	$2.79 Million
Acutus Medical Inc (AFIB)	$105.73 Million	-116.68%	0.61x	$903.35K
Adapthealth Corp (AHCO)	$280.85 Million	-57.55%	5.46x	$1.39 Billion
20/20 Biolabs, Inc. Common Stock (AIDX)	$2.15 Million	-112.84%	0.45x	$14.18 Million
Allurion Technologies, Inc. (ALUR)	$-34.28 Million	0.00%	0.00x	$9.21 Million
Autonomix Medical, Inc. Common Stock (AMIX)	$1.96 Million	-680.21%	0.05x	$3.99 Million
Artivion Inc (AORT)	$300.73 Million	-4.93%	1.64x	$1.22 Billion
Apyx Medical Inc (APYX)	$7.45 Million	9.15%	0.24x	$141.55 Million

About Boston Scientific Corp

NYSE:BSX USA Medical Devices

Market Cap

$79.98 Billion

Market Cap Rank

#322 Global

#162 in USA

Share Price

$53.93

Change (1 day)

-4.67%

52-Week Range

$53.93 - $108.14

All Time High

$108.14